Accueil / Communiqués / SIRION Biotech Expands US Presence in Massachusetts

SIRION Biotech Expands US Presence in Massachusetts

Friday, February 1st 2019 at 3:01pm UTC

Europe’s Leading Commercial Provider of Viral Vector Technology Opens
Local Office in Cambridge

CAMBRIDGE, Mass.–(BUSINESS WIRE)– SIRION
Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech
GmbH in Germany
(“SIRION”), offering the most comprehensive
portfolio of custom
viral vectors
for preclinical and clinical studies, today announced
the grand opening of a new office at 125 Cambridgepark Drive, Suite 301,
Cambridge, Massachusetts 02140. SIRION was pleased to meet its new
neighbors last night when it hosted a Bavarian-themed grand opening
event at the Forsyth
Institute
to meet and mingle with the Cambridge gene therapy scene.
World renowned gene cell therapy developers and viral vector experts
talked about the importance of the right viral vectors in making gene
therapy a reality. Gene therapy has seen strong clinical advancement,
and SIRION is becoming a partner of choice in this growing sector as
demonstrated by recent deals with Denali
Therapeutics
, Orchard
Therapeutics
, and an additional, undisclosed alliance with a major
public company that is advancing the discipline.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190201005315/en/

SIRION Biotech celebrated their move to Boston with a Grand Opening Reception at the Forsyth Institu ...

SIRION Biotech celebrated their move to Boston with a Grand Opening Reception at the Forsyth Institute in Cambridge. (Photo: Business Wire)

“As transduction and manufacturing efficiencies are critical issues in
gene therapy, SIRION’s viral vectors are essential to the success of
their partnering companies,” said Dieter Lingelbach, Chief Operating
Officer of SIRION Biotech. Dieter continued, “Since two-thirds of
SIRION’s revenue already comes from US customers and partners, opening
an office in a Life Science hub like Cambridge, Massachusetts further
demonstrates our commitment to supporting existing customers and further
expanding into the US market.”

About SIRION Biotech International Inc.

SIRION Biotech International is a wholly-owned subsidiary of SIRION
Biotech GmbH providing custom engineering and manufacturing services of
viral vectors for the life sciences industry. Its unique focus on
improving transduction efficiencies and safety make SIRION Biotech a
valuable technology partner for gene and cell therapy trials. LentiBOOSTTM
transduction reagent is actively used to improve, among others,
hematopoietic cell transductions in clinical trials. NextGen AAV capsid
evolution projects aim to improve tissue targeting and immune escape of
capsids to usher in a new generation of therapeutics for international
gene therapy companies. www.sirion-biotech.com

Contacts

Lisa DeScenza
Assistant Vice President, Integrated Communications
(978)
395-5970
ldescenza@lavoiehealthscience.com

Source: SIRION Biotech International Inc.


Voir aussi

Study Demonstrates Cook Biotech’s OASIS® Wound Matrix Has Higher Rates of Healing in Pressure Ulcers Than Standard of Care

Wednesday, February 20th 2019 at 6:30pm UTC BLOOMINGTON, Ind.–(BUSINESS WIRE)– A recently published multi-center, randomized, …